French drugmaker, Sanofi-aventis, is seeking a buyer for its U.S. dermatology business that could amount to a $433 million sale, according a Bloomberg report.
Bloomberg said the sources were “two people with knowledge of the matter” who indicated that first-round bids occurred last week but specified that the matter remains private.
Chief executive officer Chris Viehbacherin, in 2009, indicated the operation was too small and Sanofi needed to focus on treatments for diabetes, cancer and atrial fibrillation. The dermatology products produced at the unit include Sculptra Aesthetic, a wrinkle-filler that fills-in deep smile lines.
“Sanofi-Aventis U.S. is exploring strategic alternatives for the U.S. dermatology business in keeping with its strategy to reallocate resources to high-growth areas including diabetes, oncology, and atrial fibrillation,” Sanofi said in an e-mailed statement yesterday.